MDxHealth S.A.
NASDAQ:MDXHMedical - Diagnostics & Research
-$0.03 today
- Market cap
- $57.59M
- Beta
- 0.38
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$0.58
Volume 0.65M
Average 4.27M
MDXH Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
MDxHealth S.A.NASDAQ: MDXH
Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026
Selling, general & admin grows 21.3% year over year
Q2 FY2026 selling, general & admin of $19.6M rose 21.3% year over year. Over 3 fiscal years it compounded at +10.0% a year.
Context
- Selling, general & admin amounted to 61.9% of revenue in FY2025, down 6.3 pp from a year earlier.
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 4 analysts of $108.2M (+62.1%) for the fiscal year ending Dec 2026, a step up from the +8.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $19.6M— QoQ
- Last fiscal yearDec 2025
- $66.75M+8.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +21.3% | — | — |
| 1 year | +8.7% | +62.1% | +53.4 pp |
| 3-year CAGR | +10.0% | +27.0% | +17.0 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 66.75M USD
- Year-over-year change
- +8.7%
- 4-year CAGR
- +21.9%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 66.75M | +8.7% |
| FY2024 | 2024-12-31 | 61.4M | +2.5% |
| FY2023 | 2023-12-31 | 59.93M | +19.6% |
| FY2022 | 2022-12-31 | 50.12M | +65.9% |
| FY2021 | 2021-12-31 | 30.22M | — |
Selling, General & Admin vs competitors
How MDXH compares with its peers on the latest reported figures
- MDXH's FY2025 selling, general & admin of $66.75M is the 4th highest of the 11 companies compared; the peer median is $41.31M.
- Its year-over-year change of +8.7% is the 7th highest of 11, against a peer median of +11.9%.
- Selling, general & admin amounts to 61.9% of revenue for MDXH, versus a peer median of 81.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $4.7B | +29505.3% | +3.5% | — | |
| LTM Jun 2026 | $359.09M | +0.6% | +9.5% | 46.9% | |
| LTM Mar 2026 | $135.9M | +23.1% | +14.8% | 93.8% | |
| FY2025 | $66.75M | +8.7% | +10.0% | 61.9% | |
| LTM Mar 2026 | $61.76M | +68.6% | — | 114.6% | |
| LTM Mar 2026 | $47.48M | +12.9% | -3.6% | 69.4% | |
ZURAZura Bio Limited | LTM Mar 2026 | $35.14M | +1.0% | +112.2% | — |
| LTM Mar 2026 | $30.03M | -2.3% | +4.3% | 96.3% | |
| LTM Mar 2026 | $28.44M | +51.6% | +10.2% | 64.2% | |
| LTM Mar 2026 | $22.58M | +5.5% | -4.4% | 269.8% | |
| LTM Mar 2026 | $19.78M | +10.8% | -6.4% | 27.8% | |
| Peer median (excluding MDXH) | $41.31M | +11.9% | +4.3% | 81.6% | |
Competitors are the stored peer set for MDXH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 22.24M | 37.05M | 70.19M | 90.05M | 107.88M |
| Cost of Revenue | 11.68M | 17.84M | 26.26M | 34.91M | 43.43M |
| Gross Profit | 10.56M | 19.22M | 43.93M | 55.14M | 64.44M |
| Gross Margin | 47.5% | 51.9% | 62.6% | 61.2% | 59.7% |
| Research & Development | 5.59M | 7.56M | 6.38M | 10.55M | 10.35M |
| Selling, General & Admin | 30.22M | 50.12M | 59.93M | 61.4M | 66.75M |
| Operating Expenses | 37.41M | 57.12M | 71.26M | 79.86M | 79.84M |
| Depreciation & Amortization | 3.04M | 4.91M | 6.86M | 8.04M | 9.21M |
| EBITDA | (24.09M) | (36.39M) | (30.47M) | (22.02M) | (14.01M) |
| EBITDA Margin | -108.3% | -98.2% | -43.4% | -24.5% | -13.0% |
| Operating Income | (26.84M) | (37.9M) | (27.33M) | (24.72M) | (15.4M) |
| Operating Margin | -120.7% | -102.3% | -38.9% | -27.5% | -14.3% |
| Interest Income | 11K | 125K | 1.09M | 1.08M | 1.5M |
| Interest Expense | 1.88M | 2.74M | 5.77M | 7.63M | 12.16M |
| Other Income / Expenses | (2.16M) | (6.14M) | (15.77M) | (12.97M) | (19.98M) |
| Income Before Tax | (29M) | (44.04M) | (43.1M) | (37.69M) | (35.38M) |
| Pre-Tax Margin | -130.4% | -118.9% | -61.4% | -41.9% | -32.8% |
| Income Tax Expense | 0 | 0 | 1K | 382K | (1.86M) |
| Net Income | (29M) | (44.04M) | (43.1M) | (38.07M) | (33.52M) |
| Net Margin | -130.4% | -118.9% | -61.4% | -42.3% | -31.1% |
| EPS (Basic) | (2.38) | (2.78) | (1.66) | (0.78) | (0.67) |
| EPS (Diluted) | (2.38) | (2.78) | (1.66) | (1.16) | (0.67) |
| Weighted Avg Shares | 12.19M | 15.87M | 25.91M | 48.67M | 50.03M |
| Weighted Avg Shares (Diluted) | 12.19M | 15.87M | 25.91M | 48.67M | 50.03M |
MDxHealth S.A.
NASDAQ:MDXH
Intrinsic Alpha fair value
Locked
Current Price
$0.60
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.